Sara Hurvitz, MD

Articles

Dr. Hurvitz on Incidence of Male Breast Cancer

March 13th 2021

Sara A. Hurvitz, MD, discusses the incidence of male breast cancer in the United States.

Dr. Hurvitz on the Expanding Metastatic HER2+ Breast Cancer Treatment Arsenal

January 7th 2021

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.

Dr. Hurvitz on the Potential Global Impact of Biosimilars in Breast Cancer

August 23rd 2019

Sara Hurvitz, MD, associate professor, David Geffen School of Medicine, UCLA; medical director, Jonsson Comprehensive Cancer Center Clinical Research Unit; co-director, Santa Monica-UCLA Outpatient Oncology Practices; and director, Breast Cancer Clinical Trials Program, UCLA, discusses the potential global impact of biosimilars in breast cancer.

Dr. Hurvitz on the FDA Approval Process for Biosimilars

April 30th 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses when to use a biosimilar over the originator drug.

Dr. Hurvitz on Biosimilars in Breast Cancer

April 23rd 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses biosimilars in breast cancer.

Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer

June 2nd 2017

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses treatment options for patients with HER2-positive breast cancer.

Dr. Hurvitz on Eliminating Anthracyclines in HER2+ Breast Cancer Treatment

March 11th 2017

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses data supporting the elimination of anthracyclines in HER2-positive breast cancer treatment.

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

August 17th 2016

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses steps needed to take in the field of HER2-positive breast cancer from a research perspective.

Dr. Hurvitz on Neoadjuvant Therapy for HER2+ Breast Cancer

May 11th 2016

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses neoadjuvant treatment options for patients with HER2-positive breast cancer.

Dr. Hurvitz on Treatment Hypotheses for TNBC

August 6th 2014

Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, gives an overview of treatment hypotheses for triple-negative breast cancer (TNBC).

PI3K-Targeting Agents May Help Overcome Resistance in Breast Cancer Treatment

December 20th 2013

Through a variety of research roles, Sara Hurvitz, MD, is exploring novel targeted therapies for the treatment of breast cancer, including developing and implementing clinical trials. Her interests include the phosphatidylinositol 3-kinase (PI3K) signaling pathway.